Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

Rhea-AI Summary

Codex DNA (Nasdaq: DNAY) announced participation in the SVB Leerink 11th Annual Global Healthcare Conference on February 9, 2022. An updated corporate presentation will be available on February 16, 2022, at 12:00 PM ET / 9:00 AM PT. This presentation can be accessed via the investors section of the Codex DNA website.

As a leader in synthetic biology, Codex DNA provides innovative solutions, including the award-winning BioXp™ system, revolutionizing DNA and mRNA synthesis for applications in precision medicine, drug discovery, and more.

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11^th Annual Global Healthcare Conference. An updated version of Codex DNA’s corporate presentation will be available on Wednesday, February 16^th at 12:00 pm Eastern time / 9:00 am Pacific time.

The presentation can be accessed through a link on the investors section of the Codex DNA website at https://ir.codexdna.com.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly^® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate, and reproducible writing of DNA and mRNA for numerous downstream markets. The company’s award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning, and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA/RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Contact:
Richard Lepke
Director of Investor Relations
(619) 840-5392
RichardL@codexdna.com

FAQ

What is the significance of Codex DNA's participation in the SVB Leerink 11th Annual Global Healthcare Conference?

Codex DNA's participation highlights its leadership in synthetic biology and its role in advancing healthcare innovations.

When will Codex DNA's updated corporate presentation be available?

The updated corporate presentation will be available on February 16, 2022, at 12:00 PM ET / 9:00 AM PT.

How can I access Codex DNA's corporate presentation?

The corporate presentation can be accessed through the investors section of Codex DNA's website.

What technologies does Codex DNA focus on in synthetic biology?

Codex DNA specializes in automated DNA and mRNA synthesis systems, including the BioXp™ system, which enables rapid and error-free DNA/RNA production.

What markets benefit from Codex DNA's solutions?

Codex DNA's solutions are used in precision medicine, biologics drug discovery, vaccine development, and genome editing.